Show simple item record

dc.contributor.authorHoskin, Pen
dc.contributor.authorSartor, Oen
dc.contributor.authorO'Sullivan, Jen
dc.contributor.authorJohannessen, Den
dc.contributor.authorHelle, Sen
dc.contributor.authorLogue, John Pen
dc.contributor.authorBottomley, Den
dc.contributor.authorNilsson, Sen
dc.contributor.authorVogelzang, Nen
dc.contributor.authorFang, Fen
dc.contributor.authorWahba, Men
dc.contributor.authorAksnes, Aen
dc.contributor.authorParker, Cen
dc.date.accessioned2015-01-08T16:30:20Z
dc.date.available2015-01-08T16:30:20Z
dc.date.issued2014-11
dc.identifier.citationEfficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. 2014, 15 (12):1397-406 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid25439694
dc.identifier.doi10.1016/S1470-2045(14)70474-7
dc.identifier.urihttp://hdl.handle.net/10541/337972
dc.description.abstractPrimary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases. We did a prespecified subgroup analysis from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleEfficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.en
dc.typeArticleen
dc.contributor.departmentMount Vernon Cancer Centre, Northwood, Middlesex, UKen
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractPrimary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases. We did a prespecified subgroup analysis from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223.


Files in this item

This item appears in the following Collection(s)

Show simple item record